MRK vs V: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
VS
Visa Inc. · Financial Services
$304.36
+37.7% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
V has more upside to fair value
(+37.7%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
V |
| Current Price |
$121.42 |
$304.36 |
| Fair Value Estimate |
$118.00 |
$419.00 |
| Upside to Fair Value |
-2.9%
|
+37.7%
|
| Market Cap |
$300.2B |
$586.8B |
| Forward P/E |
14.0x
|
23.7x
|
| EV / EBITDA |
11.8x
|
22.3x
|
| Price / Sales |
4.1x
|
14.2x
|
| Price / FCF |
21.4x
|
25.6x
|
| Revenue Growth YoY |
+1.3%
|
+11.3%
|
| Gross Margin |
81.5%
|
81.08%
|
| Operating Margin |
41.2%
|
59.18%
|
| Return on Equity |
34.7%
|
54.22%
|
| Dividend Yield |
3.1% |
0.83% |
| FCF Yield |
4.7%
|
3.91%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Visa is the world's dominant payment network with $40B in net revenue (FY2025), 50%+ net margins, and a capital-light toll-booth model processing $14.2T in annual payment volume across 257.5B transactions. The business compounds at 10-12% revenue CAGR with operating leverage pushing EPS growth to 12-15% over a cycle, funded by $21.6B in annual free cash flow against only $1.5B in capex. At 28.0x …
Accumulation Zones
| Metric |
MRK |
V |
| Zone Low |
$88.00 |
$265.00 |
| Zone High |
$100.00 |
$300.00 |
| In Buy Zone? |
No
|
No
|